Twenty-seven years of experience with oral vitamin K1 therapy in neonates

Clark, Frank I.; James, Elizabeth

doi:10.1016/s0022-3476(95)70315-2

Cited by 14 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In summary, the reported successes of using PO vitamin K prophylaxis in neonates (29) are consistently outweighed by data supporting the preferential use of IM over PO vitamin K in newborns. The reasons for additional benefits with IM delivery are not clear, but may pertain to better storage and slow release.…”

Section: Prevention Of Late Vkdbmentioning

confidence: 97%

Guidelines for vitamin K prophylaxis in newborns

Loewy

2018

Paediatrics &Amp; Child Health

View full text Add to dashboard Cite

A joint statement with the College of Family Physicians of CanadaAll Canadian Paediatric Society position statements and practice points are reviewed regularly and revised as needed. Consult the Position Statements section of the CPS website www.cps.ca/en/documents for the most current version. Retired statements are removed from the website. AbstractNewborns are at risk for vitamin K deficiency bleeding (VKDB) caused by inadequate prenatal storage and deficiency of vitamin K in breast milk. Systematic review of evidence to date suggests that a single intramuscular (IM) injection of vitamin K at birth effectively prevents VKDB. Current scientific data suggest that single or repeated doses of oral (PO) vitamin K are less effective than IM vitamin K in preventing VKDB. The Canadian Paediatric Society and the College of Family Physicians of Canada recommend routine IM administration of a single dose vitamin K at 0.5 mg to 1.0 mg to all newborns. Administering PO vitamin K (2.0 mg at birth, repeated at 2 to 4 and 6 to 8 weeks of age), should be confined to newborns whose parents decline IM vitamin K. Health care providers should clarify with parents that newborns are at increased risk of VKDB if such a regimen is chosen. Current evidence is insufficient to recommend routine intravenous vitamin K administration to preterm infants undergoing intensive care.

show abstract

Section: Prevention Of Late Vkdbmentioning

confidence: 97%

Guidelines for vitamin K prophylaxis in newborns

Loewy

2018

Paediatrics &Amp; Child Health

View full text Add to dashboard Cite

show abstract

“…15 The incidence of late VKDB after a single oral dose reported approximately 1.4 to 6.4 per 100,000 births. 16 A study using 4 oral doses of 1 mg vitamin K1 found two babies developed late VKDB in 182 000 babies given oral prophylaxis due to undiagnosed liver disease. 17 There was no bleeding episodes of any kind in infant given 3 oral doses of vitamin K. 11 American Academy of Pediatrics (AAP) recommends vitamin K1 should be given to all newborns as a single, intramuscular dose of 0.5 to 1 mg.…”

Section: Discussionmentioning

confidence: 99%

Effect of oral vitamin K prophylaxis on prothrombine time and activated partial thromboplastin time: a randomized controlled comparison with an intramuscular vitamin K in infants

Limantara¹,

Sudaryat²,

Mudita³

et al. 2007

View full text Add to dashboard Cite

Background Low plasma concentration of vitamin K in thenewborn accounts for serious bleeding in the neonatal period andearly infancy. The aim of prophylactic vitamin K is to preventbleeding. Oral prophylaxis is preferable to intramuscular (IM)administration because oral administration is less expensive andless traumatic.Objective To compare oral vs. intramuscular vitamin K onprothrombine time (PT) and activated partial thromboplastin time(APTT) during the first 60 days of life.Methods We randomized newborn infants to either receive oralvitamin K 2 mg at birth and repeated at 7 and 30 days of life orthe 1 mg intramuscular vitamin K. PT and APTT were monitoredat 0, 15, and 45 days of age. Independent t-test, repeatedmeasurement, and regression analysis were used for statisticalanalyses and comparison of the results.Results Fifty infants were assigned into the oral group and 50 tothe IM group. All participants completed 60 days of study. BothPT and APTT decreased after administration of oral or IM vitaminK, and the values did not differ significantly at any time pointand through the period of investigation. Using regression analysisit was shown that only vitamin K administration was correlatedwith PT and APTT with P value were 0.044 and 0.036,respectively. During 60 days of study, there was no hemorrhagicdiathesis in both groups.Conclusions Through the first 60 days of life, 3 doses of oralvitamin K maintain hemostasis by decreasing PT and APTT ininfants at values equal to those achieved by the intramuscularpreparation. Diathesis hemorrhagic event did not occur in bothgroups.

show abstract

“…Como profilaxia para a doença hemorrágica do recém-nascido, a Academia Americana de Pediatria (AAP), desde 1961, tem preconizado a dose de 1 mg de vitamina K intramuscular ao nascimento. Como alternativa, alguns países têm recomendado a administração da vitamina por via oral, na dose de 2 mg ao nascimento e doses subseqüentes após o nascimento [4][5][6][7][8] .…”

Section: Discussionunclassified

Late hemorragic disease of the newborn: case report

Figueiredo¹,

Norton²,

Lamounier³

et al. 1998

J Pediatr (Rio J)

View full text Add to dashboard Cite

IntroduçãoAs manifestações clínicas predominantes da carência da vitamina K são as hemorragias, decorrentes da não ativação das proteínas dependentes da vitamina. Apesar de ocorrer em qualquer faixa etária, o recém-nascido é mais susceptível à doença, por apresentar níveis mais baixos de fatores da coagulação, menores reservas de vitamina K e por ter baixo aporte da vitamina quando alimentado com o leite humano.A doença hemorrágica do recém-nascido, causada pela deficiência de vitamina K, na sua forma clássica, é bastante conhecida dos pediatras. A sua importância clí-nica deixou de ser uma preocupação em virtude do uso de vitamina K após o nascimento como uma forma efetiva de prevenir a doença. A forma tardia da doença, descrita em trabalhos publicados na década de 80, continua sendo pouco divulgada em nosso meio. Nos países de primeiro mundo, a profilaxia da forma tardia constitui, ainda, uma preocupação. O presente estudo objetiva chamar atenção para esta forma tardia de doença, muitas vezes não lembrada pelos pediatras. ResumoObjetivo: Chamar atenção para a doença hemorrágica do recém-nascido em sua forma tardia, que poderá ter graves conseqüências, incluindo o óbito e seqüelas neurológicas.Métodos: São apresentados e descritos quatro casos de recém-nascidos, com idade variando de 12 a 21 dias de vida, diagnosticados como doença hemorrágica tardia por deficiência de vitamina K.Resultados: Nos casos apresentados as manifestações hemorrágicas foram múltiplas. Os locais acometidos em nossos casos foram o aparelho digestivo, trato urinário, côto umbilical, aparelho respiratório e SNC.Conclusão: O estudo mostra a importância da forma tardia da doença hemorrágica do recém-nascido, destacando-se sua possível gravidade, risco de morte e de seqüelas neurológicas. A administração profilática de vitamina K após o nascimento, preconizada pela OMS, continua sendo a melhor forma de prevenir a doença.J. pediatr. (Rio J.). 1998; 74(1):67-70: deficiência de vitamina K, doença hemorrágica do recém-nascido, doença hemorrágica forma tardia. AbstractObjective: In this study the authors review this subject, and call attention for the late hemorrhagic disease of the newborn, due to the severity and higher risk of mortality and neurological sequelae.Methods: In this article, four cases of children, age raging from 12 to 21 days, with late hemorrhagic disease associated with vitamin K deficiency were reported.Results: All newborns had multiple hemorrhagic manifestations of the disease. The systems more affected were digestive tract, urinary system, umbilical cord, respiratory system and nervous system.Conclusion: Three forms of hemorrhagic disease of newborn have been related with vitamin K deficiency. However, late vitamin K deficiency bleeding is not common and may not be diagnosed by pediatrician. This form of disease can be prevented by vitamin K prophylaxis administration after birth.

show abstract

Twenty-seven years of experience with oral vitamin K1 therapy in neonates

Cited by 14 publications

References 10 publications

Guidelines for vitamin K prophylaxis in newborns

Guidelines for vitamin K prophylaxis in newborns

Effect of oral vitamin K prophylaxis on prothrombine time and activated partial thromboplastin time: a randomized controlled comparison with an intramuscular vitamin K in infants

Late hemorragic disease of the newborn: case report

Contact Info

Product

Resources

About